Generic versions of semaglutide, widely known as Ozempic, are set to appear on Canadian pharmacy shelves in the coming weeks, following Health Canada approvals. Canadian drug manufacturer Apotex announced the launch of its generic version in mid-May, with initial inventory already shipped to wholesalers. The company stated that Apo-Semaglutide Injection will be available across the country shortly.
Affordable Alternatives for Patients
Apotex emphasized that the generic versions will provide patients and healthcare providers with affordable alternatives to brand-name medications. The company’s announcement highlighted that this move aims to reduce costs for those requiring semaglutide for type 2 diabetes management.
Health Canada Approvals
Canada became the first G7 nation to approve a generic semaglutide on April 28, 2026, according to Health Canada. A second generic was authorized in early May, and seven additional submissions from various companies are under review. Health Canada noted that generic medications are often 45 to 90 percent cheaper than their brand-name counterparts.
The federal department confirmed that Apotex’s submission underwent a thorough review, and like existing products, the generic injection is intended for adult patients with type 2 diabetes.
Supply and Coverage
Supply of the generic will vary by province and pharmacy, according to Shoppers Drug Mart. The pharmacy chain stated that generic semaglutide contains the same active ingredient as Ozempic and is expected to deliver the same therapeutic effect at a lower cost for eligible patients.
Semaglutide is also marketed under the brand name Wegovy for weight loss. The Canadian Medical Association (CMA) noted that health insurance coverage for weight management is limited, with only a few private plans offering partial coverage and public drug plans generally not covering it. The original formulation can cost several thousand dollars annually, making it unaffordable for many Canadians who pay out of pocket.
The CMA anticipates that as more generic versions become available, prices will drop, improving access for Canadians.
